Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | serine:threonine protein kinase 3 | 0.0696 | 1 | 1 |
Trypanosoma brucei | STE20-like serine/threonine-protein kinase 1, putative | 0.0164 | 0 | 0.5 |
Entamoeba histolytica | protein kinase, putative | 0.032 | 0.2921 | 1 |
Trichomonas vaginalis | STE family protein kinase | 0.032 | 0.2921 | 1 |
Leishmania major | protein kinase, putative | 0.0164 | 0 | 0.5 |
Brugia malayi | Protein kinase domain containing protein | 0.0587 | 0.7951 | 0.7926 |
Schistosoma mansoni | ste20-related kinase | 0.0536 | 0.6997 | 1 |
Schistosoma mansoni | serine/threonine protein kinase | 0.032 | 0.2921 | 0.4073 |
Echinococcus granulosus | leucine rich repeat serine:threonine protein | 0.0591 | 0.8026 | 0.7211 |
Plasmodium falciparum | protein kinase, putative | 0.032 | 0.2921 | 0.5 |
Loa Loa (eye worm) | TKL/LRRK protein kinase | 0.0587 | 0.7951 | 0.7926 |
Echinococcus multilocularis | leucine rich repeat serine:threonine protein | 0.0587 | 0.7951 | 0.7951 |
Loa Loa (eye worm) | STE/STE20/MST protein kinase | 0.0696 | 1 | 1 |
Loa Loa (eye worm) | STE/STE20/YSK protein kinase | 0.032 | 0.2921 | 0.2836 |
Plasmodium vivax | serine/threonine-specific protein kinase, putative | 0.032 | 0.2921 | 0.5 |
Trichomonas vaginalis | STE family protein kinase | 0.032 | 0.2921 | 1 |
Echinococcus multilocularis | serine threonine protein kinase | 0.032 | 0.2921 | 0.2921 |
Giardia lamblia | Kinase, STE STE20 | 0.0164 | 0 | 0.5 |
Trypanosoma cruzi | STE/STE20 serine/threonine-protein kinase, putative | 0.0164 | 0 | 0.5 |
Trypanosoma cruzi | STE/STE20 serine/threonine-protein kinase, putative | 0.0164 | 0 | 0.5 |
Echinococcus multilocularis | serine:threonine protein kinase 3 | 0.0696 | 1 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.